Cardeas Pharma Corporation
http://cardeaspharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Cardeas Pharma Corporation
Appointments: G1 Therapeutics, Breath Therapeutics, Fortress Biotech, Freeline Therapeutics, Enterome and Symic Bio
GSK's former CEO Sir Andrew Witty has joined the board of directors of the oncology company, G1 Therapeutics. This week's roundup also includes CEO appointments by Fortress Biotech, Freeline Therapeutics and BridgeSat, in addition to various other high-level appointments by Nabriva Therapeutics, Caribou Biosciences, Symic Bio and Breath Therapeutics.
Zavante Targets Resistant Urinary Infections With I.V. Version Of Existing Drug
If approved, Zolyd will be the first intravenous epoxide antibiotic approved in the US, with greater potency than the oral version used first-line. Ex-US, the I.V. formulation has demonstrated a stable resistance profile.
Recent Financings Of Private Companies, June 2013
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Recent Financings Of Private Companies column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies in the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Pulmonary
-
Drug Delivery
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice